1. Home
  2. EU vs PHAR Comparison

EU vs PHAR Comparison

Compare EU & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo enCore Energy Corp.

EU

enCore Energy Corp.

HOLD

Current Price

$1.49

Market Cap

361.2M

ML Signal

HOLD

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$12.58

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EU
PHAR
Founded
2009
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
361.2M
1.2B
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
EU
PHAR
Price
$1.49
$12.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$4.00
$38.33
AVG Volume (30 Days)
2.7M
10.4K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
N/A
EPS
0.03
N/A
Revenue
$43,155,000.00
N/A
Revenue This Year
$212.11
$10.04
Revenue Next Year
$29.88
$2.51
P/E Ratio
N/A
$3,041.22
Revenue Growth
N/A
N/A
52 Week Low
$1.34
$9.54
52 Week High
$4.19
$21.34

Technical Indicators

Market Signals
Indicator
EU
PHAR
Relative Strength Index (RSI) 35.08 31.19
Support Level N/A $11.43
Resistance Level $2.83 $17.41
Average True Range (ATR) 0.11 0.53
MACD -0.02 -0.09
Stochastic Oscillator 22.83 15.28

Price Performance

Historical Comparison
EU
PHAR

About EU enCore Energy Corp.

enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Share on Social Networks: